Dr Tricia Tan is a Consultant in Diabetes, Endocrinology and Metabolic Medicine at Imperial College London and NHS Trust. She possesses over 10 years’ experience in gut hormone research and physiological studies into the impact of gut hormones on weight and T2DM. She has completed several Phase I trials on the gut hormone analogues, which are being developed for the treatment of obesity. She is the director of the SAS Gut Hormone service, and her clinical research spans a wide gamut from the diagnosis and treatment of neuroendocrine tumours to diagnostic testing in Endocrine disorders.
et al., 2021, The use of whole blood capillary samples to measure 15 analytes for a home-collect biochemistry service during the SARS-CoV-2 pandemic: A proposed model from North West London Pathology., Ann Clin Biochem
et al., 2021, Safety and efficacy of an extended-release peptide YY analogue for obesity: A randomized, placebo-controlled, phase 1 trial, Diabetes Obesity & Metabolism, ISSN:1462-8902
et al., 2021, Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?, Alzheimers Research & Therapy, Vol:13
et al., 2021, Who will benefit from bariatric surgery for diabetes? A protocol for an observational cohort study, Bmj Open, Vol:11, ISSN:2044-6055
et al., 2021, Roux-en-Y Gastric Bypass Increases Glycemic Variability and Time in Hypoglycemia in Patients With Obesity and Prediabetes or Type 2 Diabetes: A Prospective Cohort Study, Diabetes Care, Vol:44, ISSN:0149-5992, Pages:614-617